HORSHOLM, Denmark--(BUSINESS WIRE)-- LifeCycle Pharma A/S (OMX:LCP) today announced positive top-line results from a completed Phase II clinical study of LCP-Tacro tablets in stable liver transplant patients which are in line with earlier data announced for stable kidney transplant patients. These new data for LCP-Tacro, a once daily immunosuppression drug to prevent rejection after organ transplantation, demonstrated that LCP-Tacro tablets also for stable liver patients have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf®, by indicating:
